This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Participants are not eligible for the trial if they have received the first dose of a COVID-19 vaccine more than seven days prior to enrollment, have previously had COVID-19 or are showing any signs or symptoms of COVID-19. About Molnupiravir.
Food and Drug Administration (FDA) approved VAXNEUVANCE ™ (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.
At 48 weeks, both trials met their primary efficacity endpoint of chance of actors with HIV-1 RNA situations ? Merck ResearchLaboratories. “ 50 clones/ mL, demonstrating that antiviral efficacity was similar between DOR/ ISL and ART ( ILLUMINATE SWITCH A) and between DOR/ ISL and BIC/ FTC/ TAF (ILLUMINATE SWITCH B).
As previously reported, at 48 weeks, both trials met their primary efficacy endpoint of percentage of participants with HIV-1 RNA levels ?50 All clinical studies provide important learnings to help us in the fight against HIV, and we are grateful to the patients and investigators for their contributions.”. About Merck.
A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different researchlaboratories. Nucleic Acids Research. Read A new DNA polymerase variant, called RT-KTq I614Y, can directly detect RNA modifications, including pseudouridine (Ψ) and queuosine (Q).
Rubin, senior vice president, global clinical development, Merck ResearchLaboratories. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.
Joan Butterton, vice chairman, global clinical development, contagious conditions, Merck ResearchLaboratories. The primary endpoint is the proportion of study actors with HIV-1 RNA viral cargo ? 50 c/ mL at Week 24. Their safety and efficacity haven’t yet been established. About Merck.
The influenza virus was not isolated until 1933, when an epidemic in London enabled British researchers Wilson Smith, Christopher Andrewes, and Patrick Laidlaw to collect human influenza virus from patients’ throat washings. Once they identified the cause, scientists in New York City and elsewhere hurried to create a vaccine.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content